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Cellular imaging: a key phenotypic
screening strategy for predictive
toxicology
Jinghai J. Xu*
Merck and Co., Kenilworth, NJ, USA
Incorporating phenotypic screening as a key strategy enhances predictivity and
translatability of drug discovery efforts. Cellular imaging serves as a “phenotypic anchor”
to identify important toxicologic pathology that encompasses an array of underlying
mechanisms, thus provides an effective means to reduce drug development failures due
to insufficient safety. This mini-review highlights the latest advances in hepatotoxicity,
cardiotoxicity, and genetic toxicity tests that utilized cellular imaging as a screening
strategy, and recommends path forward for further improvement.
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Introduction
Modernmedicines have saved countless lives. One needs only to trace the discovery of antiretroviral
drugs to marvel at its contribution to human health (Broder, 2010). However, new therapies are
necessary to address still unmet medical needs while adhering to the timeless adage of “first doing
no harm” to patients. Predictive toxicology meets the latter challenge by offering accurate and
timely predictions to minimize drug toxicity (Xu and Urban, 2010). It is recognized as a frontier
for identifying better medicines in a more cost-effective manner by biopharmaceutical research and
regulatory communities (FDA, 2010).
To successfully practice predictive toxicology, one must adopt an integrated approach utilizing
innovations frommultiple fields of science and engineering. In recent years there is a resurgence of
phenotypic screens in drug efficacy discovery (Moffat et al., 2014). Likewise to improve confidence
in the translatability of toxicity predictions, one should also incorporate phenotypic screens as a
key strategy. This is because the “phenotype” of a specific safety signal can be caused by many
underlying mechanisms and pathways, thus a reductionist “one gene/protein/mechanism to one
toxicity” approach most likely will not be sufficient. This does not mean that one should revert to
simple cell death measurements. Instead, more specific cellular functions that are vital to sustain
physiological homeostasis can serve as translational links between non-clinical tests and clinical
observations. Among many practical choices of phenotypic screens, cellular imaging technologies
can be applied as “phenotypic anchors” to identify the same histopathology that occurs in vivo.
Cellular imaging encompasses the techniques that allow quantitative detection and measurement
of cellular structures and components including organelles and biomolecules ranging from
macromolecules to small ions, often aided by automatedmicroscopes, digitized cameras, and image
analysis algorithms. Since “seeing is believing,” this “phenotype first” approach assures an unbiased
study for compounds that affect important cellular homeostasis without exhausting all possible
mechanistic tests. Of course, “phenotype first” does not preclude mechanistic investigations
to better understand the underlying reason(s) of drug safety findings. Often it is a holistic
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approach relying on mechanism-informed phenotypic test,
coupled with pharmacokinetic and pharmacodynamics (PKPD)
modeling that produces the best overall prediction toward
clinical outcome.
Hepatic Toxicity Imaging
Hepatic toxicity ranked highest in research priorities among
adverse drug reactions in the pharmaceutical industry, and
current detection systems remain imperfect especially with
regard to idiosyncratic hepatotoxicity (Opar, 2012). Key
mechanisms of drug-induced liver injury (DILI) include
oxidative stress and/or mitochondrial damage leading to
apoptosis or steatosis, and hepatobiliary transporter inhibition
leading to cholestasis (Kaplowitz, 2005; Tujios and Fontana,
2011).
Mechanism-informed phenotypic tests using cellular imaging
have been developed to encompass these key DILI mechanisms.
For example, a panel of fluorescent imaging probes has been
applied to measure oxidative stress, mitochondrial function,
glutathione content, and hepatocellular lipidosis simultaneously
in primary human hepatocytes (Xu et al., 2008). It has
demonstrated ∼60% sensitivity and ∼95% specificity for
drugs that have caused idiosyncratic DILI. This hepatocyte
imaging assay technology has been successfully applied to both
differentiate compounds for the same pharmacologic target (e.g.,
p38 MAP kinase inhibitors), and study the mechanism of DILI
signals observed in the clinic (e.g., Her2 receptor antagonist) (Xu
et al., 2011). A similar imaging approach measuring oxidative
stress in primary human hepatocytes resulted in 41% sensitivity
and 86% specificity, and was shown to have better predictivity
than HepG2 cell lines or HepG2 plus hepatic metabolism from
the liver S9 fractions (Garside et al., 2013). These studies
demonstrated the application of cellular imaging technology
to predict DILI, and highlighted the need to enhance test
sensitivity by recapitulating additional DILI mechanisms and
pathways.
Since inhibition of a panel of hepatobiliary transporters is
another known pathway of drug-induced cholestasis (Morgan
et al., 2013), cellular imaging was applied to assess transporter
functions. The assay utilized quantitative imaging of fluorescent
bile acid and its disposition in the bile canaliculi compartment
of the hepatocyte cultures (Xu et al., 2011). As protein
trafficking and sorting disturbances also play an integral part
of intrahepatic cholestasis (Hayashi and Sugiyama, 2013), whole
cell systems as opposed to isolated membrane vesicles over-
expressing one transporter at a time should continue to play
a key role in phenotypic screening of cholestasis-inducing
drugs.
Several improvements on these cellular imaging tests should
be explored to further enhance accurate prediction of DILI:
1) Long-term: Adopt a longer-term test system that maintains
differentiated metabolic functions of human liver. Recently
with advancement in iPSC-derived hepatocyte cultures,
multi-day testing appeared promising. However, these longer-
term models still need to be assessed with more DILI
negative drugs to fully assess specificity (Ware et al.,
2015).
2) Diversity: Apply more than one human liver origin with
defined genetic background to increase test sensitivity toward
idiosyncratic DILI. Patient-derived hepatic stem cells that
can be differentiated into adult hepatocyte cultures can
be interesting models to explore idiosyncratic causes of
DILI.
3) Probes: Expand fluorescent imaging probes to include
additional bile acid analogs that are substrates of
both NTCP and BSEP transporters, in addition to
cholyl lysyl fluoresceine which is a more specific
substrate for OATP/MRP transporters (de Waart et al.,
2010).
4) Inflammatory and multi-cell systems: Explore the role
of pro-inflammatory cytokines and/or Kupffer cells for
possible synergistic effects in test sensitivity without
sacrificing specificity (Cosgrove et al., 2009), and assess
the potential benefit of 3D liver chip with controlled
microfluidics.
5) Modeling: Mechanism-based PKPD modeling
approaches should be applied to integrate any in vitro
measurements into a holistic in vivo prediction
(Woodhead et al., 2014). Predictions made by the more
complex model should also be compared to simple
in vitro-in vivo scaling or classification approaches
based on exposure multiples or pre-defined safety
margins.
Cardiac Toxicity Imaging
Adverse cardiovascular effects ranked highest among safety
reasons for delayed approvals or non-approvals by the US Food
and Drug Administration (FDA) between 2000 and 2012 (Sacks
et al., 2014). Many drugs that prolong the QT interval in
electrocardiograms block the delayed rectifier K+ current (Ikr)
by blocking one key ion channel, the hERG channel. However,
not all hERG channel blockers cause QT interval prolongation
nor translate to the more severe clinical concern, torsade de
pointes [TdP, or twisting of the points in electrocardiograms
(Vargas, 2010)]. So QT prolongation is a surrogate biomarker
that is not very specific to TdP. In addition to TdP there are
other mechanisms of cardiotoxicity. Cardiovascular functional
abnormalities can also arise through impaired left ventricular
function characterized by changes in cardiomyocyte contractility
(Doherty et al., 2013). Therefore, a more holistic screening
approach is needed. Since 2013, the FDA working with other
international research communities have an on-going initiative
to develop better preclinical tools to evaluate cardiovascular
safety with the ultimate goal of preventing early stage compounds
from being unnecessarily discontinued, while still screening out
molecules that are either pro-arrhythmic or lead to changes in
cardiomyocyte contractility (Sager et al., 2014).
Synchronously beating human cardiomyocytes should be
explored as a key phenotypic screening model. Despite some
limitations of iPSC-derived cardiomyocytes, they are the future
for large-scale functional cardiotoxicity screening models in
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preclinical drug evaluation (Puppala et al., 2013). This is because
there is a virtually unlimited supply of functionally competent
cells, and there is the possibility to create cells from defined
genetic background thus lending the model amenable to further
mechanistic studies. Researchers have studied 131 drugs using
iPSC-derived cardiomyocytes, using fast kinetic imaging-based
Ca2+ flux as continuously cell-beating measurements (Sirenko
et al., 2013). Each output (beat rate, peak characteristics, and
cell viability) generated as a result of such cellular imaging assay
has yielded a panel of imaging “signatures” for understanding
the type of pathophysiological effect that a chemical may have
on the heart. Not surprisingly, beat rate and several peak
shape parameters were found to be better predictors than
simple cell viability. In another study, video-based microscopic
imaging recapitulated expected drug effects in stem-cell-derived
cardiomyocytes without the use of exogenous labels and
produced the same beat traces as patch clamp (Maddah et al.,
2015). Recently, the throughput and accuracy of iPSC-based
model to detect changes in cardiomyocyte contraction was
found applicable in drug discovery screening, with a sensitivity
and specificity of 87 and 70%, respectively (Pointon et al.,
2015).
Tyrosine kinase inhibitors (TKIs) are efficacious against
tumors harboring mutations and/or over-expressing such
kinases. However, TKIs have been hampered by cardiotoxicity
issues detected most frequently as changes in left-ventricular
ejection fraction (LVEF), which were not predicted by hERG
inhibition per se. Using multi-parameter cellular imaging it was
demonstrated while crizotinib, sunitinib, and nilotinib disrupted
the normal beat pattern of human iPSC-derived cardiomyocytes,
erlotinib did not. These alterations in iPSC-cardiomyocyte beat
pattern correlated well with known clinical cardiac outcomes of
these drugs, demonstrating the potential to use this phenotypic
screen as a routine test to identify safer compounds in a class of
drug candidates (Doherty et al., 2013).
Several improvements on these cellular imaging screens
should be explored to further enhance the overall prediction of
cardiotoxicity:
1) beating disturbances by a variety of drugs with different
cardiotoxic mechanisms
2) longer-term cellular models to study cardiac hypertrophy
3) drug metabolites by introducing hepatic metabolism (e.g.,
either hepatic S9 fraction or multi-cell systems)
4) more test qualification with large compound sets consisting
of an equal number of positive and negatives that have been
rigorously adjudicated. A balanced test set of compounds with
more negative or clean compounds is critical to assess test
specificity.
Genetic Toxicity Imaging
Carcinogenicity remained a major nonclinical safety finding
among FDA non-approvals and delayed approvals between
2000 and 2012 (Sacks et al., 2014). In one of the largest
retrospective analyses of pharmaceutical compounds to date,
it was demonstrated that significant R&D time, resources, and
animal usage can be reduced by relying on the near 100% negative
predictive values (NPV) of combined tests evaluating genetic
toxicity, hormonal perturbation, and evidence of neoplasia
in chronic rat toxicology studies (Sistare et al., 2011). To
minimize the impact of carcinogenicity findings in late-stage
drug development, both mutational and chromosomal changes
need to be evaluated as they can be caused by different underlying
mechanisms (FDA, 2012).
Cellular imaging has greatly enhanced the efficiency and
accuracy of measuring both mutational and chromosomal
changes. The Ames test remains a cost-effective stethoscope
to study genetic toxicology (Claxton et al., 2010). In order to
enable rapid scoring of mutant bacterial colonies, the Salmonella
strains used in the Ames test were engineered to express
bioluminescent proteins (Aubrecht et al., 2007). The high-
throughput imaging based on automated counting of the number
of surviving bioluminescent colonies offered a far more accurate
assessment of genotoxicity than bulk biomass measurements (Xu
and Aubrecht, 2010).
With regard to chromosomal changes, the in vitro
micronucleus test is an accepted test by regulatory authorities
(EMA and FDA) (FDA, 2012). While traditional micronucleus
test relied on manual counting of the number of micronuclei
in thousands of cells per treatment sample and hundreds of
samples per test compound, cellular imaging has made this
task more efficient. The increased throughput and accuracy
of computerized analysis of micronuclei frequency enabled
rapid structure-activity profiling of drug candidates during lead
optimization (Xu and Aubrecht, 2010).
Conclusion
From a systems perspective, since in vitro genotoxicity tests
have near 100% negative predictive value toward in vivo
genotoxicity outcome, are among the most cost-effective to
operate (i.e., using bacterial strains and mammalian cell lines),
and include both general cytotoxicity and cell growth inhibition
as integral part of assay readouts, in vitroAmes andmicronucleus
should be employed as the foundational tests to select those
“clean” compounds for further R&D investments. In the lead
optimization stage of small-molecule drug discovery, these
genotoxicity tests should be followed by cardiac and hepatic
toxicity screening using primary cells or iPSCs next, then other
organ-specific tests on an ad hoc basis last. The ad hoc tests
are reserved for program-specific purposes, e.g., triggered by
hypotheses about the mechanism-based toxicity or prior in vivo
findings for previous compounds in the program. Examples of
such ad hoc assays include: muscle, kidney, neural, teratonenic,
developmental, myelotoxicity, and lymphotoxicity. The potential
for multi-organ chip to improve toxicity prediction should also
fall into this last category until its predictivity and throughput
make it possible for front-loading (Bhatia and Ingber, 2014).
The ad hoc assays can also include further investigation of
previous positive findings, e.g., micronucleus positives can
be imaged for other markers to differentiate chromosome
breaks (clastogens) vs. chromosome loss (aneuploidy), where an
acceptable safety margin can allow for further drug development
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TABLE 1 | A summary of imaging tests and their predictive values reviewed by this article.
Cell model
(reference)
Imaging technique Threshold for positives Predictive value Example image
Human hepatocyte
(Xu et al., 2008)
Fluorescence imaging of
oxidative stress, mitochondrial
function, glutathione content
and hepatocellular lipidosis
>2.5 fold above or <2.5 fold
below the vehicle control mean
values (depending on which
fluorescence channel).
Appropriate cut-off levels were
selected using ROC curves
∼60% sensitivity
and ∼95% specificity
Human hepatocyte
(Garside et al., 2013)
Fluorescence imaging of
oxidative stress
>6 SD of the vehicle control
mean values
41% sensitivity and
86% specificity
Human hepatocyte
(Xu et al., 2011)
Fluorescence imaging of bile
acid and its disposition in bile
canaliculi
<2.5 fold below the vehicle
control mean values
TBD
iPSC-derived human
cardiomyocytes
(Sirenko et al., 2013)
Fast kinetic imaging-based
Ca2+ flux as continuously
cell-beating measurements
(beat rate, amplitude, and
other beat parameters)
>1 SD of the vehicle control
mean values
TBD
iPSC-derived human
cardiomyocytes
(Pointon et al., 2015)
Fast kinetic imaging-based
Ca2+ flux as continuously
cell-beating measurements
(peak count, average peak
amplitude, average peak
width, average peak rise time,
average peak decay time, and
average peak spacing)
The median of the positive and
negative control wells were set
at 0 and −100, respectively,
and the signals from all wells
scaled to this range.
Appropriate cut-off levels were
selected using ROC curves
87% sensitivity and
70% specificity, using
peak count
Ames (Xu and
Aubrecht, 2010)
Automated counting of the
number of surviving
bioluminescent colonies
Same as manual counting 100% combined
negative predictive
value to carcinogenicity
test
In vitro micronucleus
(Xu and Aubrecht,
2010)
Automated scoring of the
micronucleus frequency
Same as manual scoring 100% combined
negative predictive
value to carcinogenicity
test
SD, standard deviation; ROC, receiver operator characteristic; TBD, to be determined.
(Cheung et al., 2014). In the complex business of defining
drug safety, “clean” compound in all test systems are not
always realistic. One should therefore use a balanced and
holistic approach starting with defining an acceptable safety
profile for a drug candidate, understanding the predictive value
and limitation of each test system, and a “weight-of-evidence”
approach integrating findings from human cells, in vivo animal
testing, and human clinical trials. Table 1 summarizes the
imaging tests and their predictive values described in this
mini-review.
Safety deficiencies account for more than half of delayed FDA
approval or non-approval of new drug applications from 2000
to 2012 (Sacks et al., 2014). Predictive toxicology holds the key to
reduce this attrition andmake R&D investmentmore sustainable.
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To realize its promise practitioners of predictive toxicology must
continue to integrate diverse innovations from multiple fields of
biomedical engineering, including:
1) Predictive and reliable cellular models: esp., evaluation,
characterization, production, and standardization of
predictive human cells
2) Mechanism-informed phenotypic screening strategy,
including cellular imaging as a key component as it
provides a phenotypic anchor and direct linkage to in vivo
histopathology
3) Quantitative therapeutic window predictions: e.g., using
mechanism-based scaling or predictive PKPD modeling
One may envision a future when the banking of pluripotent
stem cells from individual human donor with defined genetic
makeup and subsequent expansion into fully-functional organ
parenchymal cells as a desirable model toward predicting
personalized drug responses, for both drug efficacy and safety.
But before we achieve that dream, the holistic applications of an
integrated approach as highlighted above have already marched
us a long way toward transforming toxicology to improve
product safety.
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